[Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma]

Area of Science:

• Oncology
• Pharmacology

Background:

• Multiple myeloma remains an incurable orphan disease with frequent relapses.
• Current therapies face challenges with patient relapse and refractoriness.

Purpose of the Study:

• To evaluate the efficacy of histone deacetylase inhibitors as a novel therapeutic class for multiple myeloma.
• To assess the synergistic effects of panobinostat in combination with first-line therapy.

Main Methods:

• Conducted an extensive multicenter phase III clinical trial.
• Investigated the impact of histone deacetylase inhibitors on gene expression.

Main Results:

• Panobinostat demonstrated synergistic effects on progression-free survival.
• The drug was approved by the FDA and received marketing authorization in Europe.

Conclusions:

• Histone deacetylase inhibitors represent a promising new class of anti-myeloma drugs.
• Panobinostat is the first approved histone deacetylase inhibitor for multiple myeloma treatment.